Affymetrix Blames 12 Percent Q2 Sales Drop on Weak European Performance, Sales Reorganization
July 27, 2010
Affymetrix Blames 12 Percent Q2 Sales Drop on Weak European Performance, Sales Reorganization
Despite its disappointing Q2 performance, the firm's management assuaged investors last week that all anticipated instrument orders remain in its pipeline, and that any "disruption" associated with sales restructuring has passed.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Affy Marks End of 'Days of Fixed Content Arrays,' Reaffirms Sequencing Not a 'Strategic Fit'
January 19, 2010 / BioArray News - Fisher Scientific to Distribute Affy's GeneAtlas
January 12, 2011 / GenomeWeb Daily News - Affymetrix Q1 Sales Up 2 Percent on Next-Gen Genotyping, Instrument Demand
April 27, 2010 / BioArray News - Affy Posts 6 Percent Decrease in Q2 Sales as it Prepares to Launch Next-Gen Genotyping Offering
July 28, 2009 / BioArray News - Affy's Q2 Revenues Fall 6 Percent but Beat Estimates; Shares Soar
July 23, 2009 / GenomeWeb Daily News